Nuveen LLC Makes New $93.54 Million Investment in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Nuveen LLC has acquired a new position in ADMA Biologics Inc, purchasing 4,714,861 shares valued at approximately $93.5 million, representing about 1.98% of the company.
• ADMA Biologics reported earnings per share (EPS) of $0.15 in its latest quarterly earnings, surpassing analysts' expectations of $0.14, with revenues of $121.98 million, up 13.8% year-over-year.
• Insider transactions included significant stock sales by directors Jerrold B. Grossman and Steve Elms, with a total of approximately 464,621 shares sold worth about $9.64 million over the last quarter.

Nuveen LLC purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,714,861 shares of the biotechnology company's stock, valued at approximately $93,543,000. Nuveen LLC owned about 1.98% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. B Group Inc. bought a new position in shares of ADMA Biologics in the 4th quarter worth about $39,231,000. Invesco Ltd. lifted its position in shares of ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after buying an additional 1,570,649 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of ADMA Biologics in the 4th quarter worth about $19,076,000. Dimensional Fund Advisors LP increased its holdings in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after acquiring an additional 643,661 shares during the period. Finally, Man Group plc increased its holdings in shares of ADMA Biologics by 305.5% in the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after acquiring an additional 561,507 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ADMA shares. Raymond James Financial increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

ADMA Biologics Trading Up 0.1%

Shares of ADMA traded up $0.02 during midday trading on Friday, hitting $16.99. The stock had a trading volume of 3,108,545 shares, compared to its average volume of 3,534,720. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The business has a 50-day simple moving average of $18.29 and a two-hundred day simple moving average of $18.84. The firm has a market cap of $4.05 billion, a P/E ratio of 19.76 and a beta of 0.38. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same period last year, the company posted $0.13 earnings per share. The business's revenue for the quarter was up 13.8% on a year-over-year basis. As a group, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last 90 days. 3.50% of the stock is currently owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.